Equities research analysts expect that Diplomat Pharmacy Inc (NYSE:DPLO) will report $0.23 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $0.21 to $0.24. Diplomat Pharmacy reported earnings per share of $0.25 during the same quarter last year, which suggests a negative year over year growth rate of 8%. The firm is scheduled to issue its next quarterly earnings results on Monday, August 6th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full year earnings of $0.92 per share for the current year, with EPS estimates ranging from $0.90 to $0.95. For the next year, analysts anticipate that the firm will report earnings of $1.12 per share, with EPS estimates ranging from $1.01 to $1.22. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, May 7th. The company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.01). The company had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The firm’s revenue was up 24.4% compared to the same quarter last year. During the same period last year, the company posted $0.19 EPS.
A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. raised shares of Diplomat Pharmacy from a “neutral” rating to an “overweight” rating in a report on Thursday, May 10th. Leerink Swann reissued an “outperform” rating and issued a $33.00 target price on shares of Diplomat Pharmacy in a report on Friday, June 22nd. ValuEngine raised shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a report on Saturday, June 16th. Morgan Stanley raised their price objective on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday, July 3rd. Finally, Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 9th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $26.64.
Shares of Diplomat Pharmacy traded down $0.63, reaching $26.14, on Friday, Marketbeat reports. The company had a trading volume of 727,165 shares, compared to its average volume of 897,043. The stock has a market capitalization of $2.01 billion, a P/E ratio of 31.55 and a beta of 1.33. The company has a current ratio of 0.88, a quick ratio of 0.57 and a debt-to-equity ratio of 0.59. Diplomat Pharmacy has a one year low of $14.50 and a one year high of $28.74.
In other Diplomat Pharmacy news, Director Jeffrey G. Park sold 1,695 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $25.26, for a total transaction of $42,815.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Shawn Tomasello sold 1,680 shares of the firm’s stock in a transaction that occurred on Tuesday, June 5th. The stock was sold at an average price of $24.27, for a total transaction of $40,773.60. Following the transaction, the director now owns 12,816 shares of the company’s stock, valued at approximately $311,044.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,250 shares of company stock valued at $419,364. Company insiders own 24.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Diplomat Pharmacy by 3.6% during the 4th quarter. BlackRock Inc. now owns 6,754,710 shares of the company’s stock worth $135,566,000 after buying an additional 237,500 shares during the period. Frontier Capital Management Co. LLC grew its position in shares of Diplomat Pharmacy by 2.5% during the 1st quarter. Frontier Capital Management Co. LLC now owns 3,919,051 shares of the company’s stock worth $78,969,000 after buying an additional 94,861 shares during the period. GW&K Investment Management LLC grew its position in shares of Diplomat Pharmacy by 1.9% during the 1st quarter. GW&K Investment Management LLC now owns 1,024,336 shares of the company’s stock worth $20,640,000 after buying an additional 19,222 shares during the period. Point72 Asset Management L.P. grew its position in shares of Diplomat Pharmacy by 1,424.3% during the 1st quarter. Point72 Asset Management L.P. now owns 939,562 shares of the company’s stock worth $18,932,000 after buying an additional 877,922 shares during the period. Finally, Redwood Investments LLC acquired a new stake in shares of Diplomat Pharmacy during the 1st quarter worth approximately $16,716,000. 75.66% of the stock is owned by institutional investors.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.